| Ytd | 14.95% | |
| 1y | -42.52% |
| Open | 2.42 | Prev Close | 2.42 | Low | 2.42 | High | 2.49 | Mkt Cap | 41.94M |
| Vol | 128.90K | Avg Vol | 242.06K | EPS | -0.61 | P/E | N/A | Forward P/E | -2.23 |
| Beta | -0.46 | Short Ratio | 13.35 | Inst. Own | 42.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 04-28 | Earning | 08-10 | 50-d Avg | 2.54 | 200-d Avg | 2.50 | 1yr Est | 3.40 |
VERU News
WestPark Capital analyst Ed Arce initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and a
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasi
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopha
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru (NASDAQ:VERU) reported quarterly losses of $(0.30) per share which beat the analyst consensus e
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to alrea
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing inno
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim ana
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on tr
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharm
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price crossed below its 200-day moving average du
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during tra
Veru Inc. (NASDAQ: VERU - Get Free Report)'s stock price passed below its 200-day moving average dur
-- The Phase 2b study to assess enobosarm's ability to preserve lean mass, physical function, and bo
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both sma
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biophar
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Investors are prepping for this week's earnings reports which include homebuilders, several appa
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly e
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company p
On Wednesday, 311 stocks hit new 52-week lows.
Friday's session saw 112 companies set new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterl
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings
On Wednesday, 220 stocks hit new 52-week lows.
On Monday, 76 companies set new 52-week lows.
On Friday, 93 stocks made new 52-week lows.
On Friday, 469 companies hit new 52-week lows.
On Thursday, 175 stocks hit new 52-week lows.
During Wednesday's session, 104 stocks hit new 52-week lows.
On Monday, 198 companies hit new 52-week lows.